Skip to main content
PLOS One logoLink to PLOS One
. 2025 Mar 20;20(3):e0320066. doi: 10.1371/journal.pone.0320066

Aggressive surgical approach with major vascular resection for retroperitoneal sarcomas

Yiyuan Li 1, Jichun Zhao 1, Bin Huang 1, Xiaojiong Du 1, Hankui Hu 1, Qiang Guo 1,*
Editor: Paolo Aurello,2
PMCID: PMC11957768  PMID: 40111953

Abstract

Background

En bloc resection of adjacent structures, including major vessels, is often required to achieve negative margins in retroperitoneal sarcoma (RPS). However, the effect of vascular involvement and different reconstruction techniques in patients undergoing vascular resection remains unclear. This study investigated the morbidity, mortality, and long-term survival of patients who underwent an aggressive surgical approach with vascular resection for RPS.

Methods

We analyzed a prospectively maintained database of patients who underwent surgical resection (with or without vascular resection) for RPS between 2015 and 2020. The primary endpoint was long-term overall survival (OS).

Findings

The study population comprised 252 patients. Postoperative morbidity, mortality, and OS did not differ significantly between the vascular and no vascular resection groups. Among patients with vascular involvement, those who underwent aggressive surgical approach with vascular resection had a significantly higher OS (66.3 months vs. 25.6 months) compared to those who underwent palliative resection, without an increase in mortality or complication rate. No significant differences were observed in postoperative morbidity, 30-day mortality, or estimated median OS between patients who underwent primary repair and reconstruction.

Conclusions

In patients with RPS with vascular involvement, an aggressive surgical approach with vascular resection achieved optimal clinical outcomes. Vascular reconstruction techniques had no impact on clinical outcomes.

Introduction

Aggressive resection is the most effective treatment to reduce local recurrence and improve overall survival (OS) for patients with retroperitoneal sarcomas (RPSs) [1]. Owing to the anatomical characteristics of the retroperitoneal space, RPSs are often asymptomatic and unaccompanied by the compression of adjacent organs [2]. Thus, these tumors are undetected until they are large and closely related to the large blood vessels [2]. RPSs that infiltrate or encase major vessels have been considered unresectable [3]. When the tumor and involved vessels do not have clear tissue margins or cannot be dissected from adjacent major vascular structures, the vessels must be resected and reconstructed for complete surgical resection, posing a more technically challenging surgical approach [4]. However, advances in oncovascular surgery have enabled en bloc resection of the tumors and the involved vessels [5,6].

Some trials have been performed at high-volume institutions to examine the effect of aggressive resection on RPS, but the effectiveness of this approach remains debatable [79]. However, few studies have examined the surgical technique and outcomes of patients undergoing resection of major vascular structures for RPS, and most of which are limited to case reports or series with small sample sizes owing to its rarity and technical complexity [10,11]. Limited applications and outcomes that support the feasibility of this technique have been described in these case series. Only two case-control studies have evaluated the effect of an aggressive surgical approach with vascular resection versus tumor resection alone [12,13]. The long-term survival outcomes after vascular resection and tumor resection alone are similar [12,13]. However, one of these studies only enrolled patients with primary retroperitoneal liposarcomas [12], whereas the other only reviewed the results of patients who underwent RPS resection involving only the inferior vena cava [13]. Subgroup analyses were not performed in either study. Moreover, the effect of vascular involvement and different reconstruction techniques in patients undergoing resection of major vascular structures for RPS has not been discussed. The trans-Atlantic Australasian RPS working group recently updated the consensus on managing primary RPS in adults [14]. This consensus recommended that experienced RPS surgeons should evaluate each patient for technical resectability considering technical issues associated with tumor-and patient-related variables. Thus, the estimated prognosis and expected morbidity should be considered before performing oncovascular resection.

The primary aim of this study was to investigate the safety and long-term survival outcomes of an aggressive surgical approach involving vascular resection in patients with RPS. Since there are many different vascular reconstruction techniques (primary repair, ligation, re-implantations, patch repairs, and graft reconstructions), the secondary aim of this study was to compare different reconstruction techniques to determine whether clinical outcomes differed.

Methods

Study design and patient population

We queried our prospectively maintained database at West China Hospital, Sichuan University, to identify patients with RPS who underwent surgical resection between 2015 and 2020. Exclusion criteria included patients 1) with visceral sarcomas, benign soft tissue retroperitoneal tumors, or metastatic RPS, 2) who underwent tumor-unrelated or emergency surgery, and 3) with insufficient clinical or histopathological data. The institutional review board of West China Hospital of Sichuan University approved the study protocol (IRB 2022–1674) and informed consent was waived. Patient clinical and pathological data were extracted from the hospital’s electronic medical records, anonymized, and stored in a database, maintaining strict confidentiality and being used solely for research purposes on November 24, 2022. As part of the quality improvement tracking of the analysis of existing data and follow-up survival data, the Clinical Research Unit of West China Hospital, Sichuan University trained and surveyed all the practitioners. The validation of the accuracy and completeness of the database was also supervised by the Clinical Research Unit of West China Hospital, Sichuan University. The study was registered with the Chinese Clinical Trials Registry (ChiCTR) as ChiCTR 2200066276 (https://www.chictr.org.cn/).

The preoperative characteristics, intraoperative findings, and postoperative surgical outcomes were prospectively collected and retrospectively analyzed. Patient demographic and surgical characteristics, including age, sex, body mass index (BMI), comorbid conditions, recurrence status, adjuvant treatment, margin status, organ or vascular resection, transfusion volume, and operation time, were collected. During the study period, for the patients with recurrent RPSs, we only collect the data of the fist admission. Tumor characteristics, such as histological subtype, vascular involvement, and tumor grade, were also collected. The histological subtypes were grouped as follows: well-differentiated liposarcoma (LPS), dedifferentiated LPS, leiomyosarcoma, and others. Relatively rare subtypes, such as malignant peripheral nerve sheath tumors, synovial sarcomas, undifferentiated pleomorphic sarcomas, and solitary fibrous tumors, were grouped together. Tumors were categorized according to the Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grading system as either low-risk (G1), intermediate-risk (G2), or high-risk (G3) [15]. Surgical resections were classified as macroscopically complete (R0/R1) or not (R2). Frailty was quantified using the Eastern Cooperative Oncology Group (ECOG) performance status [16]. Vascular involvement was characterized intraoperatively by the absence of a rim of normal tissue at the tumor-to-vessel interface, tumor encasement, or invasion/infiltration into adjacent major vascular structures. All the surgical procedures were performed by two surgical teams in a single center. The operating surgeon determined the need for vascular/organ resection at the time of surgery. Partial resection or accidental injury to the involved vessels was managed using primary closure or patch repair. Complete resection of the involved vessels was performed using an autologous or polytetrafluoroethylene graft. Primary anastomosis was performed when no tension was observed between the two sides of the involved vessels after complete resection. Ligation of the involved vessels was performed if the collateral circulation was preserved or the supplied organ was concomitantly resected. However, en bloc nephrectomy with ligation of the renal vein/artery was not considered vascular resection. Radiation, chemotherapy, or both were administered as neoadjuvant or adjuvant therapy to a selected group of patients after a multidisciplinary discussion. All patients were followed up every 3 months for the first year and then every 6 months through clinical evaluation and contrast-enhanced computed tomography of the abdomen every 6–12 months after surgery.

Outcomes

Patients were stratified according to the surgical strategy and categorized as no vascular resection or vascular resection group. Subgroup analyses were conducted on patients with vascular involvement during surgery and those with primary RPS. We also compared different reconstruction techniques and categorized them as primary repair or reconstruction. The primary endpoint was long-term OS. OS was defined as the time from the date of primary tumor diagnosis to the time of death or last contact. Secondary endpoints were recurrence-free survival (RFS) (the time from the date of primary tumor diagnosis to the time of disease recurrence, death, or last contact), postoperative mortality (death within 30 days after surgical resection), postoperative complication (events of Clavien–Dindo classification grade 3 or higher within 30 days after surgical resection) [17], venous thromboembolism (VTE) events (occurrence in patients without VTE before surgery who were newly diagnosed with VTE within 90 days after the operation), length of hospital stay, and length of intensive care unit (ICU) stay. Patients were screened for deep vein thrombosis (DVT) or pulmonary embolism (PE) if clinically suspected, and all symptomatic VTE events, including DVT and PE, were diagnosed objectively. DVT events were confirmed using venous ultrasonography, and PE was diagnosed using computed tomography.

Statistical analyses

Continuous patient characteristics were expressed as means with standard deviations or medians (interquartile range [IQR]) and compared using Student’s t-test or the Mann–Whitney U test, as appropriate. Categorical variables are expressed as frequency (percentage) and were compared using the chi-square test. Fisher’s exact test was used for small, expected frequencies. All the tests were two-tailed. OS and RFS were estimated using the Kaplan–Meier approach and compared between groups using a log-rank test. Statistical significance was set at p-value <  0.05. Baseline patient and tumor characteristics with a p value <  0.1 were added to the multivariable regression analysis as possible confounders using the backward stepwise method. Parsimonious models with corresponding risk-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated, with prognostic factors identified through backward selection using the likelihood ratio method. All analyses were performed using SPSS Statistics, ver. 28 (IBM Corp., Armonk, NY, USA).

Results

In total, 292 patients with RPS underwent surgical resection. Of these, 40 patients were excluded for tumor-unrelated or emergency surgery (n = 11), lost to follow-up (n = 13), or incomplete data records (n = 16) (Fig 1). The remaining 252 patients were included in this study. Concomitant organ resections were performed in 40% (102/252) of patients. The median number of resected organs among these patients was two (range, 1–5). Among the 252 patients, 51 were transferred from a local hospital and 21 underwent previous partial resection or biopsy. Furthermore, 44% (n = 110) underwent an aggressive surgical approach with vascular resection, whereas 56% (n = 142) underwent surgical resection without vascular resection. Table 1 summarizes the characteristics of patients who underwent RPS with and without vascular resection. Patients who underwent vascular resection were more likely to have been transferred from a local hospital (26.4% vs 15.5%; P =  0.033), have vascular involvement (79.1% vs 16.9%; P <  0.001), a higher FNCLCC grade (59.1% vs 45.1%; P =  0.027), history of neoadjuvant radiation (0.9% vs 7.0%; P =  0.018), more likely to have undergone organ resection (54.5% vs 29.6%; P <  0.001), and a higher transfusion rate (76.4% vs 26.1%; P <  0.001).

Fig 1. Flowchart of included patients.

Fig 1

Table 1. Baseline demographic and clinical characteristics of the study population.

Characteristic No vascular resection (n = 142) Vascular resection (n = 110) P Value
Sex (male) 67 50 0.785
Age, median (IQR) 53 (44–62) 52 (43–63) 0.468
BMI, median (IQR) 23.2 (20.3–26.4) 23.1 (20.4–25.7) 0.576
Co-morbidity
 Hypertension 15 12 0.930
 Diabetes 10 7 0.831
 Ischemic heart disease 3 2 0.868
 Cerebrovascular disease 1 1 0.856
ECOG performance status 0.227
 0 78 52
 1 56 46
 2-3 8 12
Transferred 22 29 0.033
Recurrent tumor resection 50 39 0.968
Tumor size
 <20 cm 74 50 0.294
 ≥20 cm 68 60
Pathology
 Well-differentiated LPS 31 19 0.368
 Dedifferentiated LPS 36 32 0.507
 Leiomyosarcoma 27 21 0.988
 Others 48 38 0.902
FNCLCC grade
 Low 18 8 0.162
 Moderate 60 37 0.163
 High 64 65 0.027
Neoadjuvant radiation 10 1 0.018
Neoadjuvant chemotherapy 13 6 0.270
Postoperative radiotherapy 15 12 0.930
Postoperative chemotherapy 18 15 0.823
Vascular involvement 24 87 <0.001
Margin status
 R0/1 114 94 0.283
 R2 28 16
Organ resection 42 60 <0.001
Average no. of organs resected 1.33 ± 0.87 1.57 ± 0.87 <0.001
Transfusion 37 84 <0.001
Transfusion volume (ml), median (IQR) 600 (400–1200) 1400 (800–2600) <0.001
Estimated blood loss (ml), median (IQR) 800 (600–1400) 1800 (800–3000) <0.001
30-d mortality 2 6 0.069
Complication 7 9 0.294
VTE 6 12 0.041
Length of stay (mean, d) 15.9 ± 8.1 21.2 ± 7.8 <0.001
Length of ICU stay (mean, d) 2.1 ± 1.5 3.2 ± 1.7 <0.001

Abbreviations: IQR, interquartile range; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer; LPS, liposarcoma; VTE, venous thromboembolism; ICU, intensive care unit.

Table 1 summarizes the postoperative outcomes for each group. No significant differences were observed between the vascular and non-vascular resection group in 30-day mortality (1.4% vs 5.5%) and major complications (4.9% vs 8.2%). However, the no vascular resection group had a significantly lower VTE rate than the vascular resection group (4.2% vs 10.9%; P =  0.041). Our analysis demonstrated a 5.3-day shorter mean length of hospitalization (15.9 vs 21.2 days; P <  0.001) and a 1.1-day shorter mean length of ICU stay (2.1 vs 3.2 days; P <  0.001) in the no vascular resection group compared with the vascular resection group. The median follow-up duration was 29 (IQR, 17–41) months. The 5-year OS rates of patients in the no vascular and vascular resection groups were 64% and 65%, respectively. The estimated median OS did not differ between the vascular and no vascular resection (52.4 months, 95% CI: 45.5–59.4 vs 56.0 months, 95% CI: 50.4–61.7; P =  0.268; Fig 2A) groups. Subgroup analyses of different histological subtypes revealed that the estimated median OS did not differ between the vascular and no vascular resection groups in patients with leiomyosarcoma (43.6 months, 95% CI: 35.1–52.0 vs 43.9 months, 95% CI: 27.7–60.1; P =  0.108; S1 Fig) or other sarcomas (43.5 months, 95% CI: 31.9–55.1 vs 42.5 months, 95% CI: 32.5–52.5; P =  0.975; S2 Fig). However, in patients with well-differentiated LPS, the estimated median OS was significantly shorter in the vascular resection group (49.1 months, 95% CI: 32.9–65.2) than in the no vascular resection group (72.0 months, 95% CI: 64.2–79.7; P =  0.008; S3 Fig), and the estimated median OS was significantly longer in the vascular resection group (64.1 months, 95% CI: 55.3–72.8) than in the no vascular resection group (48.3 months, 95% CI: 37.4–59.2; P =  0.016; S4 Fig) in patients with dedifferentiated LPS.

Fig 2. Overall survival of patients undergoing vascular resection and those without vascular resection for RPS in the (A) entire cohort (B) subgroup analyses cohort (patients with vascular involvement).

Fig 2

S1 Table presents the distribution of different vascular reconstruction techniques and summarizes the proportions of the major vessels involved. In total, 33 patients underwent vascular reconstruction (6 re-implantations, 3 patch repairs, and 24 graft reconstructions), and 77 patients underwent primary repair or ligation. The major vessels involved included 45 inferior vena cava, 28 iliac veins, 22 iliac arteries, 18 abdominal aortae, 23 renal veins, 21 renal arteries, and 38 other vessels.

Table 2 presents the subgroup analyses of patients with vascular involvement. In the entire cohort, 111 patients exhibited vascular involvement during surgery. In this group, 16, 27, and 24 patients had well-differentiated LPS, dedifferentiated LPS, and leiomyosarcoma, respectively. According to the FNCLCC criteria, 6, 35, and 70 cases were classified as grades 1, 2, and 3, respectively. Patients with vascular involvement had a higher proportion of high-grade tumors than those without (63.1% vs 41.8%; P =  0.001) and were more likely to have been transferred (27.9% vs 14.2%; P =  0.007). Of the 111 patients, 87 underwent an aggressive surgical approach with vascular resection, and 24 underwent palliative resection. The vascular resection approach yielded more organ resection (52.9% vs 8.3%; P <  0.001) and transfusion (74.7% vs 8.3%; P <  0.001) than the no vascular resection approach, without subsequent differences in FNCLCC grade or histopathological distribution. No differences were observed in the pathological stage distribution. Postoperative morbidity (4.2% vs 8.0%; P =  0.515), mortality (4.2% vs 5.7%; P =  0.762), VTE rate (0% vs 6.9%; P =  0.186), length of stay (18.9 ± 7.9 d vs 21.8 ± 7.6 d; P =  0.126), length of ICU stay (2.1 ± 1.7 d vs 3.5 ± 1.7 d; P =  0.178) were comparable after aggressive surgical approach and palliative resection. However, the 5-year OS rates of patients in the no vascular and vascular resection groups were 0% and 71%, respectively for those with vascular involvement. The estimated median OS was significantly shorter in the no vascular resection group (25.6 months, 95% CI: 20.0–31.3) than in the vascular resection group (66.3 months, 95% CI: 59.8–72.8; P <  0.001; Fig 2B).

Table 2. Clinicopathological and operative characteristics of patients with vascular involvement.

Characteristic No vascular resection (n = 24) Vascular resection (n = 87) P Value
Sex (male) 13 38 0.361
Age, median (IQR) 52(40–61) 53 (41–63) 0.532
Recurrent tumor resection 11 33 0.484
ECOG performance status 0.692
0 10 40
1 10 38
2-3 4 9
Transferred 5 26 0.382
Tumor size
 <20 cm 9 37 0.658
 ≥20 cm 15 50
Histology
 Well-differentiated LPS 1 15 0.106
 Dedifferentiated LPS 5 22 0.653
 Leiomyosarcoma 5 19 0.916
 Others 13 31 0.100
FNCLCC grade
 Low 1 5 0.762
 Moderate 5 30 0.203
 High 18 52 0.171
Margin status (R0/1)
 R0/1 0 79 <0.001
 R2 24 8
Organ resection 2 46 <0.001
Transfusion 2 65 <0.001
30-d mortality 1 5 0.762
Complication 1 7 0.515
Length of stay (mean, d) 18.9 ± 7.9 21.8 ± 7.6 0.126
Length of ICU stay (mean, d) 2.1 ± 1.7 3.5 ± 1.7 0.178
VTE 0 6 0.186

Abbreviations: IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group; LPS, liposarcoma; FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer; ICU, intensive care unit; VTE, venous thromboembolism.

Table 3 summarizes the demographic covariates, selected preoperative patient characteristics, and outcomes of patients who underwent surgical resection with vascular resection according to different vascular reconstruction techniques. Compared with the primary repair group, patients who underwent vascular reconstruction were more often women (75.8% vs 45.5%; P =  0.003), more likely to have leiomyosarcoma (48.5% vs 6.5%; P <  0.001), and had a higher FNCLCC grade (75.8% vs 51.9%; P =  0.020). However, no significant difference was observed in postoperative morbidity (6.5% vs 12.1%), 30-day mortality (5.2% vs 6.1%), VTE rate (7.8% vs 18.2%), length of hospital stay (20.9 ± 7.8 d vs 21.8 ± 7.9 d), and length of ICU stay (3.1 ± 1.7 d vs 3.4 ± 1.8 d) between the primary repair and reconstructed groups. Fig 3 depicts the Kaplan–Meier estimates of OS. No significant difference was observed in the estimated median OS between patients following a primary repair (49.5 months, 95% CI: 41.8–57.1) or a reconstruction (52.8 months, 95% CI: 40.5–65.1; P =  0.754; Fig 3).

Table 3. Clinicopathological and operative characteristics of patients who underwent vascular resection.

Characteristic Primary repair (n = 77) Reconstructed (n = 33)* P Value
Sex (male) 42 8 0.003
Age, median (IQR) 52(43–63) 53 (40–62) 0.753
Recurrent tumor resection 29 10 0.460
Transferred 23 6 0.202
Tumor size
 <20 cm 35 15 0.782
 ≥20 cm 42 16
Histology
 Well-differentiated LPS 19 0 0.002
 Dedifferentiated LPS 29 3 0.002
 Leiomyosarcoma 5 16 <0.001
 Others 24 14 0.255
FNCLCC grade
 Low 7 1 0.262
 Moderate 30 7 0.071
 High 40 25 0.020
Margin status (R0/1)
 R0/1 64 30 0.363
 R2 13 3
Organ resection 45 15 0.210
No. of organs resected 1.62 ± 0.84 1.40 ± 0.76 0.327
Transfusion 57 27 0.215
Transfusion volume (ml), median (IQR) 1400 (800–2600) 1300 (1000–3000) 0.348
30-d mortality 4 2 0.855
Complication 5 4 0.324
Length of stay (mean, d) 20.9 ± 7.8 21.8 ± 7.9 0.376
Length of ICU stay (mean, d) 3.1 ± 1.7 3.4 ± 1.8 0.452
VTE 6 6 0.109

Abbreviations: IQR, interquartile range; LPS, liposarcoma; FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer; ICU, intensive care unit; VTE, venous thromboembolism.

*

If a patient underwent simultaneous reconstruction and primary repair, the technique was considered as reconstruction.

Fig 3. Kaplan–Meier graph for overall survival of the patients undergoing vascular resection stratified based on different reconstruction techniques (primary repair and reconstruction).

Fig 3

Of the entire cohort, 163 patients underwent primary resection. Subgroup analyses of patients with primary RPSs did not reveal differences in baseline demographics, clinical characteristics, or outcomes (See S2 Table, which presents the clinicopathological and operative characteristics). Predictors and HRs were derived using proportional hazard Cox regression (Table 4). Multivariable analysis revealed that dedifferentiated LPS (HR: 0.231; 95% CI: 0.086–0.622; P =  0.004), FNCLCC G3 (HR: 0.279; 95% CI: 0.158–0.493; P <  0.001), and R2 resection (HR: 0.373; 95% CI: 0.166–0.838; P =  0.035) were associated with worse OS. Dedifferentiated LPS (HR: 0.486; 95% CI: 0.251–0.941; P =  0.032), FNCLCC G2 (HR: 0.498; 95% CI: 0.385–0.649; P =  0.003) or G3 (HR: 0.325; 95% CI: 0.242–0.435; P <  0.001), and R2 resection (HR: 0.452; 95% CI: 0.308–0.719; P =  0.023) independently predicted RFS. However, vascular resection did not affect RFS (no vascular resection vs. repair: HR: 0.616; 95% CI: 0.314–1.211; P =  0.160; no vascular resection vs. reconstruction: HR: 0.832; 95% CI: 0.419–1.652; P =  0.599) or OS (no vascular resection vs. repair: HR: 1.076; 95% CI: 0.461–2.509; P =  0.866; no vascular resection vs. reconstruction: HR: 1.021; 95% CI: 0.411–2.536; P =  0.964).

Table 4. Multivariate analysis of risk factors for OS and RFS for primary RPSs.

Variables OS RFS
HR 95% CI P Value HR 95% CI P Value
Age 1.005 0.989–1.021 0.570 0.994 0.981–1.006 0.317
Sex 1.102 0.639–1.901 0.727 0.727 0.480–1.101 0.132
Pathology
 Well-differentiated LPS versus Dedifferentiated LPS 0.231 0.086–0.622 0.004 0.486 0.251–0.941 0.032
 Well-differentiated LPS versus Leiomyosarcoma 0.650 0.314–1.344 0.245 1.516 0.860–2.674 0.151
 Well-differentiated LPS versus Others 0.769 0.353–1.675 0.509 0.799 0.442–1.444 0.457
FNCLCC grade
 G1 versus G2 0.578 0.326–1.021 0.063 0.498 0.385–0.649 0.003
 G1 versus G3 0.279 0.158–0.493 <0.001 0.325 0.242–0.435 <0.001
Adjuvant therapy 0.408 0.052–3.208 0.394 0.625 0.342–1.134 0.235
Vascular resected
 No vascular resection versus Repair 1.076 0.461–2.509 0.866 0.616 0.314–1.211 0.160
 No vascular resection versus Reconstructed 1.021 0.411–2.536 0.964 0.832 0.419–1.652 0.599
Organ resected 0.805 0.452–1.432 0.460 1.094 0.708–1.690 0.687
Margin status 0.373 0.166–0.838 0.035 0.452 0.308–0.719 0.023
Transfusion 1.087 0.574–2.059 0.797 1.488 0.884–2.503 0.135

Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval; RFS, recurrence-free survival; LPS, liposarcoma; FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer.

Discussion

Our findings suggest that the OS of patients with RPSs undergoing an aggressive surgical approach with or without vascular resection did not differ significantly. In addition, postoperative morbidity and short-term mortality rates were comparable between the two surgical approaches. Our results demonstrate that patients who underwent en bloc RPS resection with major vessels involved had a preponderance of long-term survival compared with those who did not undergo vascular resection, without elevated mortality or complication rates. Furthermore, our multivariable model revealed that histological subtype, pathological grade, and margin status, rather than vascular resection, were independent prognostic factors for OS and DFS. In the vascular resection group, this study demonstrated equivalent postoperative morbidity, mortality, and OS rates between the primary repair and reconstruction groups. The study results contribute to clinical decision-making by showing that vascular resection can be performed with comparable short-and long-term results in patients with RPSs.

Our study demonstrated the vascular resection group had a significantly higher blood loss, higher VTE rate, a longer mean length of hospitalization, and a longer mean length of ICU stay than the no vascular resection group, which is supported by previous studies [12,18]. Other studies have also recognized the prognostic value of malignancy grade, surgical margins, and histological type for RPS [19,20]. In this study, patients receiving vascular resection had more radical baseline characteristics because patients who underwent vascular resection were more likely to have been transferred from a local hospital, have vascular involvement, a higher FNCLCC grade, a history of neoadjuvant radiation, and were more likely to undergo organ resection. However, the complete resection rates (R0/R1) after vascular resection were comparable. Thus, although there was a higher blood loss, higher VTE rate, longer length of stay, and length of ICU stay, vascular resection achieved similar OS. The implications of higher blood loss, VTE rates, and extended ICU stays seemed low except for possible higher medical costs.

Histological examination revealed that patients with vascular involvement had a higher proportion of high-grade tumors than those without vascular involvement, indicating more aggressive behavior. Subgroup analysis of patients with vascular involvement revealed that aggressive surgical approach and palliative resection had similar postoperative morbidity and mortality rates. However, the palliative resection group had a significantly shorter estimated median OS than the vascular resection group. A previous meta-analysis assessing the relative benefits and disadvantages of an aggressive surgical approach with contiguous organ resection in patients with RPS revealed no significant differences in OS and RFS rates between the extended and tumor resection alone groups. However, organ resection did not increase postoperative mortality but increased the complication rate [21]. Further, OS was higher in R0 than in R1 and in R1 than in R2. Therefore, adjacent organs with evidence of direct invasion must be resected to avoid R2 resection. Hence, we suggest that RPS should be indicated for curative-intent resection, even with vascular involvement, and adjacent major vessels should be resected en bloc to avoid R2 resection.

Since recurrent RPS is associated with a worse prognosis than primary RPS [22], and repeat surgery is associated with a significant risk of morbidity and mortality [23], to eliminate the implications of previous procedures, we performed a subgroup analysis of patients with primary RPS. This analysis did not reveal differences in baseline demographics, clinical characteristics, or outcomes. We also performed a multivariable regression analysis of OS and RFS. We found neither primary repair nor reconstruction technique was an independent predictor of OS or RFS. Patients who underwent vascular reconstruction were often women, more likely to have leiomyosarcoma, and had a higher FNCLCC grade than those in the primary repair group. High heterogeneity was observed across previous studies in that most patients who underwent vascular reconstruction had leiomyosarcomas, and most were women [24]. However, no significant difference was observed in the short-term and survival outcomes between the primary repair and reconstruction groups. The possible explanation is that the most frequently involved major vessel is the inferior vena cava, and aggressive surgical approach and reconstruction of the inferior vena cava can be performed with very low morbidity and mortality and is associated with a low incidence of postoperative symptoms of venous hypertension [25]. Besides, as mentioned above, for retroperitoneal RPS with vascular involvement, regardless of the extent of vascular resection, only histological subtype, pathological grade, and margin status were independent prognostic factors for survival outcomes. Our surgical strategy for retroperitoneal RPS with vascular involvement achieved optimal short-term and survival outcomes, and vascular resection is feasible and safe regardless of the extent of vascular involvement.

The inferior vena cava was the most commonly resected vessel (41%), followed by the iliac vein (25%) and artery (20%), renal vein (21%) and artery (19%), and abdominal aorta (16%). Similar proportions of resected vessels have been reported in other studies [26,27]. However, the proportion of vascular resection and distribution of reconstruction techniques differed from those reported in other studies [26,27]. Based on the results of the previous series, approximately 18–25% of patients with RPS underwent vascular resection, whereas 44% of patients underwent vascular resection in our study [26,27]. In addition to complete resection of involved vessels reconstructed by autologous/synthetic graft or primary anastomose, partial resection or accidental injury of involved major vessels during the exposure of the tumor-vessel border managed with primary closure or ligation was also defined as vascular resection in our study. In addition, we defined vascular involvement as no rim of normal tissue in the tumor-to-vessel interface, tumor encasement, or invasion/infiltration into adjacent major vascular structures, resulting in higher proportions of patients with vascular involvement and patients undergoing vascular resection than that in previous studies. However, the reconstruction rate in this study was 13% (33/252), which is consistent with those reported in previous studies [26,27].

Oncovascular surgery is cancer resection with concurrent ligation or reconstruction of a major vascular structure [28]. Studies have continually supported the feasibility and safety of oncovascular resection [29]. Oncovascular resection enhances resection margins and allows considerable oncologic outcomes in various tumor pathologies with major vascular involvement, including pancreatic cancer, renal cell carcinoma, and cholangiocarcinoma [30]. However, despite the introduction of aggressive surgical approach of RPS with vascular involvement more than two decades ago [27], there have been no advancements in surgical techniques [25], and the incidence of ‘unresectability’ reported by referral centers remains high, ranging from 10–25% [8]. Upfront unresectability was owing to poor performance status and/or involvement of critical central vascular structures [8]. Here, 20% of the patients were transferred from a local hospital, and 40% of them underwent previous partial resections or biopsies, making our follow-up operations more challenging. Thus, patients with major vessel involvement should be referred to specialized centers and evaluated by an experienced, multidisciplinary team. In addition, guidelines or consensus for the surgical management of RPS are needed to establish new recommendations on aggressive surgical approaches with vascular resection based on the latest evidence, and additional prospective multicenter studies with objective criteria for vascular resection and technical non-resectability are warranted to confirm the reproducibility of the findings of this study.

This study has several limitations. The largest limitation of this study is selection bias due to the retrospective nature of the study. However, while all the surgical procedures were performed by two surgical teams and the surgical policy didn’t change over the years, selection bias might be controlled. Furthermore, no propensity score matching was performed, as it would reduce the number of included patients. In this study, vascular involvement was defined as no rim of normal tissue in the tumor-to-vessel interface, tumor encasement, or invasion/infiltration into adjacent major vascular structures, thus, invasion status and surgical margin status were based on intraoperative findings but was not confirmed via pathology. Besides, the operating surgeon evaluated each patient for technical resectability and determined the need for vascular/organ resection at the time of surgery. It would be subjective for the definition of clinical characteristics of the study population. However, unlike epithelial tumors or adenocarcinomas, which develop within a single organ, RPSs have poorly defined anatomic borders owing to their large size and multiple central locations. Therefore, assessing clear margin status is impractical. Finally, although we performed a subgroup analysis to investigate the effect of vascular involvement during surgery and in patients with primary RPS, other factors, such as FNCLCC grade, were not evaluated because of the small sample size.

In conclusion, this study reveals that for patients with RPS, aggressive resection surgical approach with vascular resection can be performed safely with an acceptable level of postoperative morbidity and equivalent long-term survival to that without vascular resection. Curative-intent en bloc resection should be performed, and adjacent major vessels with signs of involvement should be resected to avoid R2 resection. Safety and long-term survival results were not associated with the reconstruction techniques. However, the histological subtype, pathological grade, and margin status were independently associated with OS and DFS. Patients with RPS and vascular involvement are best referred to specialized centers and managed by an experienced multidisciplinary team.

Supporting information

S1 Table. Characteristics of vascular resection.

(DOCX)

pone.0320066.s001.docx (16.9KB, docx)
S2 Table. Clinicopathological and operative characteristics of patients who underwent vascular resection for primary RPSs.

(DOCX)

pone.0320066.s002.docx (19KB, docx)
S1 Fig. Overall survival of patients undergoing vascular resection and those without vascular resection for leiomyosarcoma.

(TIF)

pone.0320066.s003.tif (36MB, tif)
S2 Fig. Overall survival of patients undergoing vascular resection and those without vascular resection for other sarcomas.

(TIF)

pone.0320066.s004.tif (805.8KB, tif)
S3 Fig. Overall survival of patients undergoing vascular resection and those without vascular resection for well-differentiated LPS.

(TIF)

pone.0320066.s005.tif (36MB, tif)
S4 Fig. Overall survival of patients undergoing vascular resection and those without vascular resection for dedifferentiated LPS.

(TIF)

pone.0320066.s006.tif (36MB, tif)
S1 Data. Data set.

(RAR)

pone.0320066.s007.rar (31.5KB, rar)

Acknowledgments

The authors thank D.Y. Kang, a statistician at the Department of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, for his assistance with the statistical analysis.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The effort of Dr. Qiang Guo was partially supported by the Natural Science Foundation of Sichuan Province No. 2022NSFSC1388. Other authors do not have any funding source to declare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Fairweather M, Gonzalez RJ, Strauss D, Raut CP. Current principles of surgery for retroperitoneal sarcomas. J Surg Oncol. 2018;117(1):33–41. doi: 10.1002/jso.24919 [DOI] [PubMed] [Google Scholar]
  • 2.Gladdy RA, Gupta A, Catton CN. Retroperitoneal sarcoma: fact, opinion, and controversy. Surg Oncol Clin N Am. 2016;25(4):697–711. doi: 10.1016/j.soc.2016.05.003 [DOI] [PubMed] [Google Scholar]
  • 3.Homsy P, Blomqvist C, Heiskanen I, Vikatmaa L, Tukiainen E, Numminen K, et al. Multidisciplinary oncovascular surgery is safe and effective in the treatment of intra-abdominal and retroperitoneal sarcomas: a retrospective single centre cohort study and a comprehensive literature review. Eur J Vasc Endovasc Surg. 2020;60(5):752–63. doi: 10.1016/j.ejvs.2020.05.029 [DOI] [PubMed] [Google Scholar]
  • 4.Tzanis D, Bouhadiba T, Gaignard E, Bonvalot S. Major vascular resections in retroperitoneal sarcoma. J Surg Oncol. 2018;117(1):42–7. doi: 10.1002/jso.24920 [DOI] [PubMed] [Google Scholar]
  • 5.Finlay B, Bednarz J, Dawson J. A multidisciplinary approach to oncological resections with vascular surgeons improves patient outcomes. Eur J Vasc Endovasc Surg. 2020;60(2):293–9. doi: 10.1016/j.ejvs.2020.04.011 [DOI] [PubMed] [Google Scholar]
  • 6.Poultsides GA, Tran TB, Zambrano E, Janson L, Mohler DG, Mell MW, et al. Sarcoma resection with and without vascular reconstruction: a matched case-control study. Ann Surg. 2015;262(4):632–40. doi: 10.1097/SLA.0000000000001455 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Villano AM, Zeymo A, Nigam A, Chan KS, Shara N, Unger KR, et al. Radical excision for retroperitoneal soft tissue sarcoma: a national propensity-matched outcomes analysis. Surgery. 2020;168(5):831–7. doi: 10.1016/j.surg.2020.05.031 [DOI] [PubMed] [Google Scholar]
  • 8.Ikoma N, Roland CL, Torres KE, Chiang Y-J, Wang W-L, Somaiah N, et al. Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: a retrospective cohort study at a major sarcoma center. J Surg Oncol. 2018;117(6):1188–94. doi: 10.1002/jso.24951 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tropea S, Mocellin S, Damiani G, Stramare R, Aliberti C, Del Fiore P. Recurrent retroperitoneal sarcomas: clinical outcomes of surgical treatment and prognostic factors. Eur J Surg Oncol. 2021;471201–6. [DOI] [PubMed] [Google Scholar]
  • 10.Fiore M, Colombo C, Locati P, Berselli M, Radaelli S, Morosi C, et al. Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava. Ann Surg Oncol. 2012;19(2):511–8. doi: 10.1245/s10434-011-1954-2 [DOI] [PubMed] [Google Scholar]
  • 11.Wortmann M, Alldinger I, Böckler D, Ulrich A, Hyhlik-Dürr A. Vascular reconstruction after retroperitoneal and lower extremity sarcoma resection. Eur J Surg Oncol. 2017;43407–15. [DOI] [PubMed] [Google Scholar]
  • 12.Spolverato G, Chiminazzo V, Lorenzoni G, Fiore M, Radaelli S, Sanfilippo R, et al. Oncological outcomes after major vascular resections for primary retroperitoneal liposarcoma. Eur J Surg Oncol. 2021;47(12):3004–10. doi: 10.1016/j.ejso.2021.06.035 [DOI] [PubMed] [Google Scholar]
  • 13.Blair AB, Reames BN, Singh J, Gani F, Overton HN, Beaulieu RJ, et al. Resection of retroperitoneal sarcoma en-bloc with inferior vena cava: 20 year outcomes of a single institution. J Surg Oncol. 2018;118(1):127–37. doi: 10.1002/jso.25096 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Desai A, Gladdy RA, et al. Management of Primary Retroperitoneal Sarcoma (RPS) in the adult: an updated consensus approach from the transatlantic Australasian RPS Working Group. Ann Surg Oncol. 2021;28(12):7873–88. doi: 10.1245/s10434-021-09654-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62. doi: 10.1200/JCO.1997.15.1.350 [DOI] [PubMed] [Google Scholar]
  • 16.Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55. [PubMed] [Google Scholar]
  • 17.Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. doi: 10.1097/01.sla.0000133083.54934.ae [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Guo Q, Zhao J, Du X, Hu H, Huang B. Incidence, risk factors, and outcomes of venous thromboembolism in patients undergoing surgery for retroperitoneal tumors: a propensity-matched retrospective cohort study. Int J Surg. 2023;109(9):2689–95. doi: 10.1097/JS9.0000000000000429 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Yang J-Y, Kong S-H, Ahn HS, Lee H-J, Jeong S-Y, Ha J, et al. Prognostic factors for reoperation of recurrent retroperitoneal sarcoma: The role of clinicopathological factors other than histologic grade. J Surg Oncol. 2015;111(2):165–72. doi: 10.1002/jso.23783 [DOI] [PubMed] [Google Scholar]
  • 20.Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Le Cesne A. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27:31–7. [DOI] [PubMed] [Google Scholar]
  • 21.Guo Q, Zhao J, Du X, Huang B. Survival outcomes of surgery for retroperitoneal sarcomas: A systematic review and meta-analysis. PLoS One. 2022;17(7):e0272044. doi: 10.1371/journal.pone.0272044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228(3):355–65. doi: 10.1097/00000658-199809000-00008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lehnert T, Cardona S, Hinz U, Willeke F, Mechtersheimer G, Treiber M, et al. Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. Eur J Surg Oncol. 2009;35(9):986–93. doi: 10.1016/j.ejso.2008.11.003 [DOI] [PubMed] [Google Scholar]
  • 24.Ikoma N, Torres KE, Lin HY, Ravi V, Roland CL, Mann GN, et al. Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery. J Surg Oncol. 2017;116(3):313–9. doi: 10.1002/jso.24667 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Quinones-Baldrich WJ, Farley S. Techniques for inferior vena cava resection and reconstruction for retroperitoneal tumor excision. J Vasc Surg Venous Lymphat Disord. 2013;1(1):84–9. doi: 10.1016/j.jvsv.2012.10.056 [DOI] [PubMed] [Google Scholar]
  • 26.Bertrand MM, Carrère S, Delmond L, Mehta S, Rouanet P, Canaud L, et al. Oncovascular compartmental resection for retroperitoneal soft tissue sarcoma with vascular involvement. J Vasc Surg. 2016;64(4):1033–41. doi: 10.1016/j.jvs.2016.04.006 [DOI] [PubMed] [Google Scholar]
  • 27.Schwarzbach MHM, Hormann Y, Hinz U, Leowardi C, Böckler D, Mechtersheimer G, et al. Clinical results of surgery for retroperitoneal sarcoma with major blood vessel involvement. J Vasc Surg. 2006;44(1):46–55. doi: 10.1016/j.jvs.2006.03.001 [DOI] [PubMed] [Google Scholar]
  • 28.Ghosh J, Bhowmick A, Baguneid M. Oncovascular surgery. Eur J Surg Oncol. 2011;37(12):1017–24. doi: 10.1016/j.ejso.2011.08.131 [DOI] [PubMed] [Google Scholar]
  • 29.Sallam K, Khairy H. Oncovascular surgery and the making of the oncovascular surgeon. Vasc Specialist Int. 2019;35(4):189–92. doi: 10.5758/vsi.2019.35.4.189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Woo HY, Ahn S, Min S, Han A, Mo H, Ha J, et al. Crucial roles of vascular surgeons in oncovascular and non-vascular surgery. Eur J Vasc Endovasc Surg. 2020;60:764–71. [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Paolo Aurello

20 Dec 2024

PONE-D-24-31199Aggressive surgical approach with major vascular resection for retroperitoneal sarcomasPLOS ONE

Dear Dr. Guo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 03 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Paolo Aurello

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

3. Thank you for stating the following financial disclosure: 

This research was supported by the Natural Science Foundation of Sichuan Province No. 2022NSFSC1388.  

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

This research was supported by the Natural Science Foundation of Sichuan Province No. 2022NSFSC1388.

The authors thank D.Y. Kang, a statistician at the Department of Evidence-based Medicine and Clinical

Epidemiology, West China Hospital, Sichuan University, Chengdu, for his assistance with the statistical analysis.

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

 This research was supported by the Natural Science Foundation of Sichuan Province No. 2022NSFSC1388.

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. Please remove all personal information, ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set. 

Note: spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file.

Additional guidance on preparing raw data for publication can be found in our Data Policy (https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data) and in the following article: http://www.bmj.com/content/340/bmj.c181.long.

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear author,

First of all, congratulations on your research. Your sample is consistent. However, I would like to make some considerations.

1. Regarding the method, although the sample is prospective, your work is "retrospective". This aspect should be mentioned.

2. It is also mentioned that this research was registered in the Clinical Trials Registry. Does this mean that there is an ongoing protocol?

3. Shouldn't a stratified analysis have been performed for each histological type?

4. Considering the high number of histological types, which were the other types, should be mentioned and analyzed.

5. The resectability and unresectable criteria depended on the surgeon's assessment. Don't you consider this to be too subjective?

6. The secondary objectives were not very clear.

7. Regarding the R0, R1 resection margin criteria, why was there no statistical difference in the two groups?

8. The high number of R2 patients in the vascular resection group is noteworthy.

This type of disease is very aggressive and does not respond well to adjuvant or neoadjuvant therapy. However, it should be noted that due to the complexity of the surgery, it should only be performed in centers with expertise in oncological surgery and vascular surgery.

Finally, considering the high prevalence of retroperitoneal tumor cases in your center, we also suggest carrying out a prospective and controlled study, analyzing more objective variables.

Thanks.

Reviewer #2: This study evaluates the safety and outcomes of aggressive en bloc resection with vascular involvement in retroperitoneal sarcoma (RPS). It demonstrates that vascular resections improve long-term survival without increasing morbidity or mortality. The findings support curative-intent vascular resections as a feasible strategy for patients with RPS and vascular involvement and are highly relevant for improving survival outcomes and patient care strategies. The manuscript addresses an important and underexplored topic- vascular resections in retroperitoneal sarcoma (RPS), which has significant implications for surgical oncology practice.

This study has used a prospectively maintained database to ensure a robust dataset for analysis. It uses subgroup analyses, including reconstruction techniques, to enhance the depth of the study and allow nuanced conclusions. The manuscript is well-organized, with a logical flow from background to discussion. The data presented in tables and Kaplan-Meier curves is clear. It provides valuable evidence supporting the safety and feasibility of en bloc vascular resections and adds to existing literature by highlighting the potential of aggressive surgical approaches in improving long-term outcomes.

However, I have come across certain issues with the manuscript that need to be addressed to be accepted for publication in this journal.

Some of the major changes are:

1. Although the rationale for the study has been discussed in the introduction section, this section should present a more detailed comparison with recent studies on vascular resections in RPS. Also, the authors should consider highlighting the advancements or gaps addressed by this study.

2. The authors should consider providing more context on how the analysis of baseline differences between vascular and non-vascular resection groups occurs (like in the case of propensity score matching).

3. The authors should elaborately discuss why patients with higher FNCLCC grades were more prevalent in the vascular resection group.

4. Please discuss the implications of higher blood loss, VTE rates, and extended ICU stays for patient outcomes in detail.

5. The authors should highlight the potential strategies to mitigate these risks in clinical practice address the lack of significant differences in overall survival between primary repair and reconstruction techniques and propose hypotheses for these findings.

6. The authors should consider discussing the lack of pathology-confirmed vascular invasion and its impact on findings in a more elaborate manner while discussing the limitations.

7. The authors should mention if any efforts were made to control institutional biases due to the single-center nature of the study.

8. In the figures and tables section, the authors should add a summary table comparing key outcomes across reconstruction techniques for easier reference. Please ensure that all figures (e.g., Kaplan-Meier plots) are annotated with clear legends and relevant p-values for subgroup comparisons.

9. In the discussion section, the authors should include recommendations for multicenter studies or randomized trials to validate findings. They should suggest areas for innovation in surgical techniques or perioperative management to further improve outcomes.

I also found a few minor issues in the manuscript and working on them can improve the manuscript:

1. The authors should reassess sentence structures in the abstract and conclusion to make the findings more concise and impactful.

2. Inconsistent use of terminologies in the manuscript reduces the clarity of the manuscript and might confuse the readers. Therefore, the authors should ensure the use of terminologies consistently throughout the manuscript (for example the authors should either use “en bloc resection” or “aggressive surgical approach” and these terms should not be used interchangeably).

Overall, the manuscript seems promising and has substantial merit in contributing to the field. I believe that addressing these points mentioned above will further strengthen the study’s impact and clarity and make it suitable for acceptance to the journal.

Reviewer #3: 1.Abstract has to be still concise . FNLCC grade need not come in the abstract

2. Vascular involvement in cases has to mentioned not only in tables but also in discussion

3. No difference in OS has to be explained

4.limitations of retrospective data to be highlighted

5.better English

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes:  J.sakthiushadevi

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Comments from the reviewers.docx

pone.0320066.s008.docx (19KB, docx)
PLoS One. 2025 Mar 20;20(3):e0320066. doi: 10.1371/journal.pone.0320066.r003

Author response to Decision Letter 1


4 Feb 2025

Detailed Response to Reviewers

Reply to reviewer #1

Dear reviewer:

We appreciate your attitude to scientific review process and thank you for your comments!

Reviewer #1: Dear author,

First of all, congratulations on your research. Your sample is consistent. However, I would like to make some considerations.

1. Regarding the method, although the sample is prospective, your work is "retrospective". This aspect should be mentioned.

Response:

Yes, our work is "retrospective". We have stated in the limitation part as “this was a retrospective comparative cohort study of prospectively collected data”.

2. It is also mentioned that this research was registered in the Clinical Trials Registry. Does this mean that there is an ongoing protocol?

Response:

The study was registered with the Chinese Clinical Trials Registry (ChiCTR) as ChiCTR 2200066276 (http://www.chictr.org.cn/enindex.aspx). However, it’s not an ongoing protocol, it’s a registered retrospective study.

3. Shouldn't a stratified analysis have been performed for each histological type?

Response:

We have made a stratified analysis for each histological type in the revised paper.

4. Considering the high number of histological types, which were the other types, should be mentioned and analyzed.

Response:

As stated in the second paragraph of method part, in this study, relatively rare subtypes, such as malignant peripheral nerve sheath tumors, synovial sarcomas, undifferentiated pleomorphic sarcomas, and solitary fibrous tumors, were grouped together as ‘others’. Since each of the histological type had less than 20 cases, we didn’t analyzed them seperately.

5. The resectability and unresectable criteria depended on the surgeon's assessment. Don't you consider this to be too subjective?

Response:

Guidelines on the surgical management of RPS are still lacking and remain controversial, owing to its low incidence. For example, the criteria for unresectability remains undefined, and the indication and eligibility for surgical resection vary by medical centre. That is why we conducted this study. We have added a statetment in the limitation part.

6. The secondary objectives were not very clear.

Response:

We have made a revision.

7. Regarding the R0, R1 resection margin criteria, why was there no statistical difference in the two groups?

Response:

In this study, we did not check the tumour margin status routinely. We have added a statetment in the limitation part. Unlike the more common epithelial tumours or adenocarcinomas, which develop within a single organ, RPS can infiltrate multiple surrounding organs owing to their large size and multiple central location. Tumours measuring 20 cm on average have poorly defined anatomic borders, and thus, it would impractical to assess margin status.

8. The high number of R2 patients in the vascular resection group is noteworthy.

Response:

Sixteen of the 110 patients in the vascular resection group were R2 patients. Only 8 of the 16 patients were patients with vascular involvement, the other 8 patients were managed using primary closure or patch repair because of accidental injury to the involved vessels.

This type of disease is very aggressive and does not respond well to adjuvant or neoadjuvant therapy. However, it should be noted that due to the complexity of the surgery, it should only be performed in centers with expertise in oncological surgery and vascular surgery.

Finally, considering the high prevalence of retroperitoneal tumor cases in your center, we also suggest carrying out a prospective and controlled study, analyzing more objective variables. Thanks.

Response:

We are making efforts on carrying out prospective and controlled studies on retroperitoneal tumor cases. Thank you!

Reply to reviewer #2

Dear reviewer:

We appreciate your attitude to scientific review process and thank you for your comments!

Reviewer #2: Reviewer’s Comments

Article: Aggressive surgical approach with major vascular resection for retroperitoneal sarcomas.

This study evaluates the safety and outcomes of aggressive en bloc resection with vascular involvement in retroperitoneal sarcoma (RPS). It demonstrates that vascular resections improve long-term survival without increasing morbidity or mortality. The findings support curative-intent vascular resections as a feasible strategy for patients with RPS and vascular involvement and are highly relevant for improving survival outcomes and patient care strategies. The manuscript addresses an important and underexplored topic- vascular resections in retroperitoneal sarcoma (RPS), which has significant implications for surgical oncology practice.

This study has used a prospectively maintained database to ensure a robust dataset for analysis. It uses subgroup analyses, including reconstruction techniques, to enhance the depth of the study and allow nuanced conclusions. The manuscript is well-organized, with a logical flow from background to discussion. The data presented in tables and Kaplan-Meier curves is clear. It provides valuable evidence supporting the safety and feasibility of en bloc vascular resections and adds to existing literature by highlighting the potential of aggressive surgical approaches in improving long-term outcomes.

However, I have come across certain issues with the manuscript that need to be addressed to be accepted for publication in this journal.

Some of the major changes are:

1. Although the rationale for the study has been discussed in the introduction section, this section should present a more detailed comparison with recent studies on vascular resections in RPS. Also, the authors should consider highlighting the advancements or gaps addressed by this study.

Response:

We have adjusted a part of the content of discussion part to introduction section.

2. The authors should consider providing more context on how the analysis of baseline differences between vascular and non-vascular resection groups occurs (like in the case of propensity score matching).

Response:

No propensity score matching was performed as it would reduce the number of included patients. However, we performed a subgroup analysis to investigate the effect of vascular involvement during surgery and in patients with primary RPS, and we made a stratified analysis for each histological type in the revised paper.

3. The authors should elaborately discuss why patients with higher FNCLCC grades were more prevalent in the vascular resection group.

Response:

We stated in the third paragraph of discussion part as ‘Histological examination revealed that patients with vascular involvement had a higher proportion of high-grade tumors than those without vascular involvement, indicating more aggressive behavior’.

4. Please discuss the implications of higher blood loss, VTE rates, and extended ICU stays for patient outcomes in detail.

We have made a revision in the third paragraph of discussion part.

5. The authors should highlight the potential strategies to mitigate these risks in clinical practice address the lack of significant differences in overall survival between primary repair and reconstruction techniques and propose hypotheses for these findings.

We have made a revision in the fifth paragraph of discussion part.

6. The authors should consider discussing the lack of pathology-confirmed vascular invasion and its impact on findings in a more elaborate manner while discussing the limitations.

Response:

We have made a revision in the limitation part.

7. The authors should mention if any efforts were made to control institutional biases due to the single-center nature of the study.

Response:

As part of the quality improvement tracking of the analysis of existing data and follow-up survival data, the Clinical Research Unit of West China Hospital, Sichuan University trained and surveyed all the practitioners. The validation of the accuracy and completeness of the database was also supervised by the Clinical Research Unit of West China Hospital, Sichuan University. In addition, while all the surgical procedures were performed by two surgical teams and the surgical policy didn't change over the years, selection bias might be controlled. We have made a revision in the method part and the limitation part.

8. In the figures and tables section, the authors should add a summary table comparing key outcomes across reconstruction techniques for easier reference. Please ensure that all figures (e.g., Kaplan-Meier plots) are annotated with clear legends and relevant p-values for subgroup comparisons.

Response:

Results of postoperative morbidity, 30-day mortality, VTE rate, length of hospital stay, and length of ICU stay between the primary repair and reconstructed groups were listed in Table 3. We have made a revision of Fig 2 and Fig 3.

9. In the discussion section, the authors should include recommendations for multicenter studies or randomized trials to validate findings. They should suggest areas for innovation in surgical techniques or perioperative management to further improve outcomes.

Response:

We have made a revision.

I also found a few minor issues in the manuscript and working on them can improve the manuscript:

1. The authors should reassess sentence structures in the abstract and conclusion to make the findings more concise and impactful.

Response:

We have made a revision.

2. Inconsistent use of terminologies in the manuscript reduces the clarity of the manuscript and might confuse the readers. Therefore, the authors should ensure the use of terminologies consistently throughout the manuscript (for example the authors should either use “en bloc resection” or “aggressive surgical approach” and these terms should not be used interchangeably).

Response:

We have made a revision.

Overall, the manuscript seems promising and has substantial merit in contributing to the field. I believe that addressing these points mentioned above will further strengthen the study’s impact and clarity and make it suitable for acceptance to the journal.

Reply to reviewer #3

Dear reviewer:

We appreciate your attitude to scientific review process and thank you for your comments!

Reviewer #3:

1. Abstract has to be still concise. FNLCC grade need not come in the abstract

Response:

We have deleted the content of FNLCC grade in the revised abstract.

2. Vascular involvement in cases has to mentioned not only in tables but also in discussion

Response:

Discussion on vascular involvement was in the third paragraph of the discussion part.

3. No difference in OS has to be explained

Response:

We have made a discussion in the second paragraph of the discussion part.

4. limitations of retrospective data to be highlighted

Response:

We have made a revision in the limitation part.

5. better English

Response:

The manuscript was finally edited by Elsevier Language Editing Services (Order reference No.:ASLEPLUS0451814).

Attachment

Submitted filename: Response to Reviewers.docx

pone.0320066.s010.docx (30.2KB, docx)

Decision Letter 1

Paolo Aurello

13 Feb 2025

Aggressive surgical approach with major vascular resection for retroperitoneal sarcomas

PONE-D-24-31199R1

Dear Dr. Qiang Guo,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Paolo Aurello

Academic Editor

PLOS ONE

Acceptance letter

Paolo Aurello

PONE-D-24-31199R1

PLOS ONE

Dear Dr. Guo,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Paolo Aurello

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Characteristics of vascular resection.

    (DOCX)

    pone.0320066.s001.docx (16.9KB, docx)
    S2 Table. Clinicopathological and operative characteristics of patients who underwent vascular resection for primary RPSs.

    (DOCX)

    pone.0320066.s002.docx (19KB, docx)
    S1 Fig. Overall survival of patients undergoing vascular resection and those without vascular resection for leiomyosarcoma.

    (TIF)

    pone.0320066.s003.tif (36MB, tif)
    S2 Fig. Overall survival of patients undergoing vascular resection and those without vascular resection for other sarcomas.

    (TIF)

    pone.0320066.s004.tif (805.8KB, tif)
    S3 Fig. Overall survival of patients undergoing vascular resection and those without vascular resection for well-differentiated LPS.

    (TIF)

    pone.0320066.s005.tif (36MB, tif)
    S4 Fig. Overall survival of patients undergoing vascular resection and those without vascular resection for dedifferentiated LPS.

    (TIF)

    pone.0320066.s006.tif (36MB, tif)
    S1 Data. Data set.

    (RAR)

    pone.0320066.s007.rar (31.5KB, rar)
    Attachment

    Submitted filename: Comments from the reviewers.docx

    pone.0320066.s008.docx (19KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0320066.s010.docx (30.2KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES